Buy Dimephosphone vials 15%, 100 ml
  • Buy Dimephosphone vials 15%, 100 ml


1257 Items
Dosage form
Brand & Manufacturer
Package Size
  • done All payments are SSL encrypted
  • done Full Refund if you haven't received your order
  • done International shipping to the USA, UK and Europe

Clinical Pharmacology

DIEMPHOSPHAN improves the regulation of cerebral circulation, normalizes the reactions of cerebral vessels and blood supply to the brain, improves venous outflow.

In violation of cerebral circulation relieves vasomotor cephalgia; reduces heart and respiratory failure central origin.

Normalizes the acid-base state in acidosis of various etiologies. It exhibits membrane stabilizing, anti-inflammatory, immunomodulatory, antihypoxant, antimutagenic and radioprotective actions, inhibits platelet aggregation.

When applied topically, it has an antiseptic effect, increases the protective function of the skin and mucous membranes.


Cerebral circulatory disorders, neurosurgical surgery of the brain and spinal cord, head injury, Meniere's syndrome and disease, autonomic dysfunction, acute and chronic diseases of the respiratory organs with subcompensated pulmonary hypertension, bronchospastic variant of bronchial obstruction (chronic bronchitis, bronchitis, bronchitis, bronchial obstruction, chronic bronchitis, bronchitis, bronchial obstruction, chronic bronchitis, chronic bronchitis , acidosis of various etiologies. Atopic bronchial asthma and pollinosis in children, infectious-inflammatory and allergic diseases of the skin and mucous membranes.


Active ingredients: dimethyloxobutylphosphonyl dimethyl 15 g

Excipients: purified water to 100 ml.

No customer reviews for the moment.

Write your review

Write your review


Dosage and Administration

Inside, swallowing whole and squeezed fluid. 60 mg 3 times a day or 90 mg 2 times a day. The optimal daily dose of Diltiazem is 180-360 mg. In stationary conditions, under the supervision of a physician, the dose may be increased to 480 mg / day.

Adverse reactions

Nervous system and sensory organs: headache, dizziness, fainting, fatigue, asthenia, sleep disturbances, drowsiness, anxiety, extrapyramidal (parkinsonian) disorders (ataxia, mask-like face, shuffling gait, stiffness of arms or legs, hand shake and fingers, difficulty swallowing), depression; when used in high doses - paresthesia, tremor, visual impairment (transient vision loss).

Since the cardiovascular system: asymptomatic reduction of blood pressure; rarely, angina pectoris, arrhythmia (including flutter and ventricular fibrillation), bradycardia (less than 50 beats / min) or tachycardia, AV block II-III st. up to asystole, development or aggravation of heart failure; when used in high doses and with a / in the introduction - angina, bradycardia, AV blockade, marked reduction in blood pressure, worsening of chronic heart failure.

On the part of the digestive system: dry mouth, increased appetite, nausea, vomiting, constipation or diarrhea, increased activity of hepatic transaminases, gingival hyperplasia (bleeding, soreness, swelling).

From the hematopoietic system: rarely - thrombocytopenia, agranulocytosis.

Severe bradycardia, AV block II and III degrees (except for patients with a pacemaker), SSSU, cardiogenic shock, atrial fibrillation in WPW syndrome and Launa-Ganoga-Levine, myocardial infarction with congestive lung symptoms, hypotension, chronic heart failure II Stage B-III, acute heart failure, hemodynamically significant aortic stenosis, abnormal liver and kidney function, pregnancy, lactation, hypersensitivity to benzothiazepine derivatives.

Drug interactions

Potentially dangerous are combinations with beta-blockers, quinidine and other antiarrhythmic drugs of class Ia, cardiac glycosides (excessive bradycardia, slowing AV conduction, reducing myocardial contractility with the development of signs of HF). Procainamide, quinidine, and others. Drugs that cause the Q-T interval to lengthen, increase the risk of its significant lengthening. May increase the bioavailability of propranolol. Means for inhalation anesthesia (hydrocarbon derivatives), thiazide diuretics, and other drugs that reduce blood pressure, increase the hypotensive effect of diltiazem. Cimetidine increases the concentration of diltiazem in the blood; phenobarbital, diazepam, rifampicin - reduce. Increases blood concentrations of cyclosporine, carbamazepine, theophylline, quinidine, valproic acid and digoxin (may require a dose reduction). Perhaps the simultaneous appointment of nitrates (including prolonged forms). Strengthens the cardiodepressive effect of general anesthetics. Li + drugs can enhance the neurotoxic effect of diltiazem (nausea, vomiting, diarrhea, ataxia, tremors and / or tinnitus). Indomethacin (and other NSAIDs), GCS and estrogens, as well as sympathomimetic drugs reduce the hypotensive effect.

Special instructions

Diltiazem is used with caution in AV grade I blockade, intraventricular conduction disorders, in patients prone to arterial hypotension, chronic heart failure, myocardial infarction with left ventricular failure, ventricular tachycardia with dilated ORS complex, liver failure, renal failure, elderly patients, renal failure, elderly patients with ventricular tachycardia , in children (efficacy and safety have not been studied).

  • Brand name: Diltiazem
  • Active ingredient: Diltiazem
  • Dosage form: pills of prolonged action.
  • Manufacturer: Alkaloid
  • Country of Origin: Macedonia

Studies and clinical trials of Dimephosphone (Click to expand)

  1. Effects of dimephosphone, xydiphone, and ionol on the content and activities of rat liver cytochromes P-450 during long-term treatment with phenobarbital
  2. Effects of dimephosphone, xydiphone, and ionol on the content and activities of rat liver cytochromes P-450 during long-term treatment with phenobarbital
  3. Mechanisms of the Effect of Dimephosphone on Synaptic Transmission in the Frog Neuromuscular Junction
  4. Therapeutic Efficiency of Dimephosphone and Xydiphone in Experimental Pulse Therapy with Prednisolone
  5. Effect of Dimephosphone (Monophosphonate) on the Course of Pregnancy and Fetal Development in Rats
  6. Investigation of conformational state of molecules of dimephosphone H3C-(C=O)CH2-C(CH3)2-(P=O)(OCH3)2by means of vibrational (IR, Raman) spectroscopy and molecular mechanics
  7. IR Spectral study of the drug, dimephosphone, in aqueous media
  8. Dimephosphone effect on vessel wall antiaggregating potential
  9. Dimephosphone analogs: I. Synthesis and structure of some dimephosphone aryl- and acylhydrazones
  10. Development of the pharmaceutical composition micephosphone containing dimephosphone and its study by modeling osteoporosis
  11. Dimephosphone analogues. 3. Molecular and crystal structure of dimephosphone pyridinoylhydrazones exhibiting antiphthisic activity
  12. Synthesis and Structure of Dimephosphone Pyridinoylhydrazones with Antimycobacterial Activity
  13. Dimephosphone analogs: II. Dialkyl(diaryl)-(2-methyl-4-oxopent-2-yl)phosphine oxide oximes: Synthesis, structure, and generation of iminoxyl radicals
  14. Synthesis and Therapeutic Use of Dimephosphone
  15. Effects of Dimephosphone on Mineral Metabolism of High Dose Prednisolone Treated Rats Compared to Etidronic Acid
  16. Dimephosphone analogs: a pharmacological aspect

8 other products in the same category: